Skip to NavigationSkip to content

EMA begin review of GSK & Vir COVID-19 treatment

Published on 10/05/21 at 10:53am
GSK building

The EMA has begun a rolling review of GSK and Vir’s sotrovimab treatment for COVID-19, which will continue until there is enough evidence available for a marketing authorisation application for the drug.

The review will evaluate the treatment in adults and adolescents with COVID-19 who do not require further oxygen supply, and who are at risk of progressing to severe COVID-19.

A rolling review is often used by the EMA to speed up an assessment of a drug. The CHMP will review data of sotrovimab as it becomes available, rather than waiting for a formal application, meaning an opinion can be reached sooner.

The decision to start the review is based on the interim analysis from the Phase III COMET-ICE trial, which evaluated sotrovimab as a monotherapy for the early treatment of COVID-19 in adults at high risk of hospitalisation.

Results of the analysis, based on data from 583 randomised patients, demonstrated an 85% reduction in deaths, or hospitalisations over 24 hours, in those receiving sotrovimab as compared to those on a placebo.

A separate review of sotrovimab is also underway to provide recommendations for countries in the EU who may decide on the use of the medicine for COVID-19 prior to marketing authorisation.

An Emergency Use Authorization (EUA) application for sotrovimab has already been submitted to the FDA in the US, while it is also under review by other global regulators, including Health Canada under the expedited Interim Order application pathway for COVID-19 drugs.

Sotrovimab is a COVID-19 monoclonal antibody. Pre-clinical data suggest it has the potential to both block viral entry into healthy cells and clear infected cells. The antibody binds to an epitope on SARS-CoV-2 (COVID-19) that is shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, and less likely to mutate over time.

Jack Goddard

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches